ImportRefusal LogoImportRefusal

Malladi Drugs & Pharmaceuticals Ltd

⚠️ Moderate Risk

FEI: 3002780785 • Vellore, Tamil Nadu • INDIA

FEI

FEI Number

3002780785

📍

Location

Vellore, Tamil Nadu

🇮🇳

Country

INDIA
🏢

Address

No. 7b & 7c Sipcot Industrial Complex, , Ranipet, Vellore, Tamil Nadu, India

Moderate Risk

FDA Import Risk Assessment

40.9
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

12
Total Refusals
3
Unique Violations
3/15/2016
Latest Refusal
2/25/2005
Earliest Refusal

Score Breakdown

Violation Severity
68.7×40%
Refusal Volume
41.3×30%
Recency
0.0×20%
Frequency
10.8×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

1612×

DIRECTIONS

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.

1182×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

751×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

Refusal History

DateProductViolationsDivision
3/15/2016
60CQS10PSEUDOEPHEDRINE HCL (ADRENERGIC)
16DIRECTIONS
Philadelphia District Office (PHI-DO)
12/10/2014
60CAS10PSEUDOEPHEDRINE HCL (ADRENERGIC)
118NOT LISTED
16DIRECTIONS
75UNAPPROVED
Chicago District Office (CHI-DO)
6/7/2005
61XBS08CHLORPHENIRAMINE MALEATE (ANTI-HISTAMINIC)
16DIRECTIONS
New York District Office (NYK-DO)
6/7/2005
64HBS08BROMPHENIRAMINE/DM HBR/PSEUDOEPHEDRINE (EXPECTORANT)
16DIRECTIONS
New York District Office (NYK-DO)
6/7/2005
64HBS08BROMPHENIRAMINE/DM HBR/PSEUDOEPHEDRINE (EXPECTORANT)
16DIRECTIONS
New York District Office (NYK-DO)
6/7/2005
62UDS99ANTI-TUSSIVE/COLD N.E.C.
16DIRECTIONS
New York District Office (NYK-DO)
6/7/2005
62UDS99ANTI-TUSSIVE/COLD N.E.C.
16DIRECTIONS
New York District Office (NYK-DO)
5/3/2005
60CBS99ADRENERGIC N.E.C.
16DIRECTIONS
New York District Office (NYK-DO)
5/3/2005
60CBS99ADRENERGIC N.E.C.
16DIRECTIONS
New York District Office (NYK-DO)
5/3/2005
64HBS08BROMPHENIRAMINE/DM HBR/PSEUDOEPHEDRINE (EXPECTORANT)
16DIRECTIONS
New York District Office (NYK-DO)
5/3/2005
64HBS08BROMPHENIRAMINE/DM HBR/PSEUDOEPHEDRINE (EXPECTORANT)
16DIRECTIONS
New York District Office (NYK-DO)
2/25/2005
60CBS99ADRENERGIC N.E.C.
118NOT LISTED
16DIRECTIONS
New York District Office (NYK-DO)

Frequently Asked Questions

What is Malladi Drugs & Pharmaceuticals Ltd's FDA import refusal history?

Malladi Drugs & Pharmaceuticals Ltd (FEI: 3002780785) has 12 FDA import refusal record(s) in our database, spanning from 2/25/2005 to 3/15/2016.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Malladi Drugs & Pharmaceuticals Ltd's FEI number is 3002780785.

What types of violations has Malladi Drugs & Pharmaceuticals Ltd received?

Malladi Drugs & Pharmaceuticals Ltd has been cited for 3 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Malladi Drugs & Pharmaceuticals Ltd come from?

All FDA import refusal data for Malladi Drugs & Pharmaceuticals Ltd is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.